This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of gum잇몸의 악성신생물 (치은암)

Contents and key points
ItemDetails
A. Classification codesICD-10: C03 | Special Copayment Reduction: V193 (copayment 5% for care for this diagnosis for 5 years from the date of cancer patient registration)
B. SynonymsGingival cancer, gum cancer; Gingival carcinoma, Gingival squamous cell carcinoma (GSCC), Alveolar ridge carcinoma, Gum cancer
C. Adult onsetLikelihood of first onset in adulthood very high — mostly diagnosed in the 50s–70s, with a mean age at diagnosis of about 60
1. HistoryDeveloped together with the history of oral cancer, the long-standing challenge of differentiating gum and periodontal lesions, establishment of combined radiation and surgery in the 20th century
2. CausesSmoking, alcohol, chronic irritation from ill-fitting prostheses and residual roots, poor oral hygiene, betel nut, immunosuppression
3. GeneticsTP53·CDKN2A·FAT1·NOTCH1 somatic mutations, EGFR overexpression, molecular mechanisms of bone invasion related to mandibular invasion
4. General epidemiology10–25% of all oral cancers, higher proportion in East and South Asia than in Western countries, male predominance (1.5:1), mainly in the 50s–70s
5. PathophysiologyPremalignant lesions of keratinized mucosa (leukoplakia·erythroplakia) → multistep carcinogenesis, invasion of the mandibular cortical bone (direct infiltration·alveolar canal), activation of the EGFR and PI3K pathways
6. SymptomsEarly: gum ulcer resembling periodontitis or stomatitis, tooth mobility; advanced: nonhealing extraction socket, pain, trismus, neck mass
7. SignsUlcerative gum mass, tooth mobility and spontaneous tooth loss, osteolysis on radiographs, cervical lymphadenopathy, mandibular paresthesia (inferior alveolar nerve)
8. ScreeningRegular dental checkups (key), oral visual examination, detection of gingival cancer during periodontal examination, intensive management of high-risk groups
9. DiagnosisCT (essential evaluation of bone invasion)·MRI·PET-CT, dental panoramic X-ray, tissue biopsy, AJCC 8th edition TNM staging
10. TreatmentSurgery (marginal or segmental mandibulectomy+neck dissection), adjuvant IMRT, concurrent chemoradiotherapy, reconstruction (bone free flap), immunotherapy
11. Prognosis5-year survival rate 46.5% (overall), markedly worse with bone invasion or lymph node metastasis; diagnostic delay is a decisive prognostic factor
12. PreventionSmoking cessation and reduced alcohol, regular dental checkups, oral hygiene, correction of ill-fitting prostheses, early treatment of premalignant lesions
13. ReferencesSquamous cell carcinoma of the gingiva: A diagnostic enigma (PMC, 2015) ... and 9 other papers

1. History

Gingival cancer (malignant neoplasm of the gum) is clinically very similar to periodontal disease and inflammatory gum lesions, even among oral malignancies, so misdiagnosis and diagnostic delay have historically been frequent. Records of oral ulcers and gum tumors appear in ancient Egyptian and Greek literature, but clear recognition of gingival cancer became possible only after the establishment of modern pathology.

In 19th-century Europe, surgical resection of gingival tumors was attempted along with the development of oral surgery. Surgeons including Theodor Billroth performed resections of oral and jaw tumors, but high mortality due to recurrence and bone invasion was a problem. The discovery of X-rays in the early 20th century opened the way to radiological evaluation of mandibular invasion by gingival cancer, and with the development of dental panoramic X-ray and CT, evaluation of the extent of bone invasion became precise.

In the 1920s–1960s, radical neck dissection and extensive jaw resection became the standard surgery for gingival cancer. The introduction of radiation therapy contributed to lowering recurrence rates as postoperative adjuvant therapy. However, because gingival cancer has a lower response rate to radiation alone than other oral cancers, surgery remained the first-line treatment.

In the 21st century, with the standardization of preoperative staging using MRI and PET-CT, adjuvant radiation therapy using IMRT, and mandibular reconstruction using free vascularized bone flaps (fibula free flap, iliac crest free flap), the functional and aesthetic outcomes of gingival cancer treatment have greatly improved. The introduction of immunotherapy (pembrolizumab, nivolumab) has broadened treatment options for recurrent and metastatic gingival cancer. In Korea, a multidisciplinary approach involving collaboration among oral and maxillofacial surgery, otolaryngology, and radiation oncology is becoming standard.


2. Causes

The risk factors for gingival cancer are similar to those of other oral cancers, but interaction with the periodontal environment is particularly emphasized.

Smoking and alcohol consumption

Carcinogens in tobacco smoke act directly on the gingival mucosa, causing DNA damage. Smokeless tobacco in particular comes into direct contact with the gums and greatly increases the risk of gingival cancer. Alcohol increases the permeability of the oral mucosa to carcinogens and shows a synergistic carcinogenic effect when combined with smoking.

Chronic mechanical irritation

Chronic repetitive mechanical irritation from the sharp edges of ill-fitting dentures, retained roots, poorly fitting crowns, and poor dental fillings causes chronic ulceration of the gingival mucosa and increases the risk of malignant transformation. A state of chronic periodontal inflammation due to poor oral hygiene also creates a supplementary carcinogenic environment.

Betel nut and oral hygiene

Betel nut (areca nut) chewing comes into direct contact with the gums and oral mucosa, supplying carcinogens such as arecoline, and is therefore a major cause of gingival cancer in Southeast and South Asia. Poor oral hygiene maintains overgrowth of periodontal pathogens and a state of chronic inflammation, forming an environment that promotes carcinogenesis.

Immunosuppression and other factors

Use of immunosuppressants after organ transplantation and HIV infection increase the risk of persistent HPV infection and oral cancer. A history of radiation exposure (previous head and neck radiation therapy) is also a risk factor for secondary oral cancer. Nutritional deficiencies (vitamins A, C, E) and Plummer-Vinson syndrome (iron deficiency) have also been reported as risk factors.


3. Genetics

The molecular genetic characteristics of gingival cancer are similar to those of oral squamous cell carcinoma in general; most are HPV-negative, and accumulation of somatic mutations from smoking and alcohol is the main carcinogenic mechanism.

Major somatic mutations

TP53 mutations (about 60–80%) are the most common, and loss of DNA damage surveillance function results in inhibition of apoptosis and genomic instability. CDKN2A (p16) deletion or methylation promotes escape from cell cycle control, and loss-of-function mutations of FAT1·NOTCH1 contribute to abnormal cell adhesion and inhibition of differentiation. Activating mutations of PIK3CA hyperactivate the PI3K/AKT/mTOR pathway. CASP8 mutations confer resistance to apoptosis.

Bone invasion and molecular mechanisms

Invasion of the mandibular cortical bone, a characteristic of gingival cancer, is related to osteoclast activation. RANKL (receptor activator of NF-κB ligand) and PTHrP (parathyroid hormone-related protein) secreted by tumor cells activate osteoclasts to promote osteolysis, and MMPs (matrix metalloproteinases) are involved in degradation of the bone matrix. EGFR overexpression promotes tumor proliferation and invasion and is being studied as a therapeutic target.

Hereditary syndromes and pharmacogenomics

Carriers of Fanconi anemia have a greatly increased risk of oral cancer due to defective DNA double-strand repair. In recurrent and metastatic gingival cancer, evaluation of eligibility for pembrolizumab using PD-L1 CPS is needed. TMB and MMR deficiency status are also used to predict response to immunotherapy.


4. General epidemiology

Gingival cancer is a relatively uncommon subtype of oral cancer, accounting for about 10–25% of all oral squamous cell carcinomas. Whereas it accounts for less than 10% of all oral cancers in Europe and North America, its proportion is higher in East Asia (China, Korea) and South Asia.

Global and Korean incidence

According to GLOBOCAN 2022, oral cancer (excluding the lip) occurs in about 389,000 cases annually worldwide, of which gingival cancer accounts for 10–25%. In China, gingival cancer is reported to be the second most common oral cancer after tongue cancer. In Korea, separate statistics on the exact proportion of gingival cancer among all oral cancers are limited, but in the site distribution of head and neck squamous cell carcinoma the gingiva accounts for an important share along with tongue cancer and floor of mouth cancer. A 2025 Spanish epidemiological study reported an increasing trend in the age-standardized incidence of gingival cancer between 2001 and 2022.

Sex and age distribution

Gingival cancer occurs more often in men than in women, at a ratio of about 1.5:1. The main age of onset is the 50s–70s, with a mean age at diagnosis of about 60. Incidence increases with age, which is related to the cumulative long-term exposure to smoking and alcohol.

Distribution by site

Gingival cancer occurs most often in the posterior mandible (mandibular molar gingiva), followed by the anterior mandible and the maxillary gingiva. Gingival cancer of the posterior mandible invades the mandibular cortical bone and medullary cavity relatively early.


5. Pathophysiology

The development of gingival cancer is explained as a multistep carcinogenic process progressing from normal keratinized gingival mucosa through premalignant lesions to invasive cancer. The gingival mucosa is keratinized and relatively resistant to physical irritation, but chronic repetitive injury causes dysplasia.

Premalignant lesions and dysplasia

Oral leukoplakia, erythroplakia, and other oral dysplastic lesions arising on the gingiva become precursor lesions of gingival cancer. In an environment of chronic periodontal inflammation, inflammatory mediators (IL-6, TNF-α, increased COX-2 activity) can promote carcinogenesis. As DNA damage from smoking and betel nut accumulates, TP53 and CDKN2A mutations occur and the disease progresses to the premalignant stage.

Mechanism of mandibular invasion

One of the most characteristic pathogenetic mechanisms of gingival cancer is invasion of the mandibular cortical bone. Gingival cancer directly infiltrates the surrounding alveolar bone or spreads to the medullary cavity through the alveolar canal. Osteoclast-mediated osteolysis (RANKL/RANK pathway) and MMP activity are the main mechanisms of bone destruction. The presence and extent of bone invasion determine the surgical approach (marginal vs. segmental resection) and prognosis.

Major signaling pathways

Hyperactivation of the EGFR/RAS/MAPK pathway and the PI3K/AKT/mTOR pathway promotes cell proliferation, invasion, and angiogenesis. The Wnt/β-catenin pathway also contributes to invasive growth. In the tumor microenvironment, immunosuppressive cytokines (TGF-β, IL-10) and regulatory T cells (Treg) suppress antitumor immunity.


6. Symptoms

Because gingival cancer is clinically very similar to periodontal disease or stomatitis in the early stage, misdiagnosis and diagnostic delay are the biggest clinical problem. The average period from symptom onset to confirmed diagnosis is often more than 6 months.

Early symptoms

The most common early symptom is a painless ulcer or swelling of the gum. Patients often mistake this for simple gum inflammation, periodontitis, or irritation from ill-fitting dentures. When tooth mobility occurs, differentiation from periodontitis becomes even more difficult. Gum bleeding, redness of the alveolar area, and leukoplakic or erythroplakic changes are also early presentations. Poor wound healing and a nonhealing socket after tooth extraction are also important findings suggestive of gingival cancer.

Advanced symptoms

As the tumor grows, pain on chewing and odynophagia appear. As invasion of the mandibular cortical bone progresses, invasion of the inferior alveolar nerve causes sensory abnormalities (numbness, tingling) of the lower lip and chin. With invasion of the pterygoid muscle, trismus appears. In some cases, a neck mass due to cervical lymph node metastasis is the first symptom.

Systemic symptoms

In advanced cancer, weight loss, loss of appetite, and generalized fatigue accompany the disease. Malnutrition due to impaired oral intake is common.


7. Signs

Findings on oral inspection and palpation

An ulcerative mass or exophytic mass with irregular margins is seen on the gum. White keratinized tissue, necrosis, and bleeding accompany it on the surface. It is most often found in the posterior mandible, and mobility or spontaneous loss of adjacent teeth is observed. On bimanual palpation, the tumor feels hard, and the degree of deep invasion can be assessed.

Radiological findings

On dental panoramic X-ray or CT, moth-eaten pattern osteolysis, destruction of the alveolar bone, and loss of cortical bone are observed. Differentiation from bone loss due to periodontal disease is important, and irregular margins and rapid progression suggest malignancy.

Neck and neurological findings

Ipsilateral cervical level I·II·III lymphadenopathy is observed. With invasion of the inferior alveolar nerve, decreased sensation or paresthesia of the lower lip and chin (Vincent sign) appears. There is no specific tumor marker on blood tests, but anemia and hypoalbuminemia may be present.


8. Screening

Because gingival cancer arises at a site that can be inspected within the mouth, regular dental checkups are the most effective screening method. Dentists and oral and maxillofacial surgeons play a key role in early diagnosis by finding gingival lesions during oral mucosal examination.

National oral cancer screening and regular dental checkups

Oral cancer visual examination is included in the Korean national cancer screening system, and it is important to detect leukoplakia, erythroplakia, and ulcerative lesions of the gingival mucosa during regular dental checkups. In particular, gum ulcers lasting more than 2 weeks, nonhealing wounds after tooth extraction, and unexplained tooth mobility require immediate referral for tissue biopsy.

Management of high-risk groups

Smokers and drinkers, people with ill-fitting prostheses or retained roots, and patients with oral premalignant lesions need dental checkups and inspection of the oral mucosa at 3–6 month intervals. Patients with hereditary risk factors such as Fanconi anemia need more intensive surveillance.

Optical diagnostic aids

Oral mucosal fluorescence devices such as VELscope (autofluorescence endoscope) are used as adjuncts for visualizing premalignant lesions and early malignant lesions. Toluidine blue staining is also used to highlight dysplastic tissue.


9. Diagnosis

Imaging

CT (range including dental panoramic view and jaw, bone window): essential for evaluating the extent of invasion of the mandibular cortical bone and medullary cavity. The surgical approach (marginal vs. segmental mandibulectomy) is decided according to the presence of bone invasion. MRI: excellent for evaluating the extent of soft tissue invasion, perineural invasion (inferior alveolar nerve invasion), and medial pterygoid muscle invasion. PET-CT: used to evaluate cervical lymph node and distant metastasis. Dental panoramic X-ray is useful as an initial screening tool, but CT/MRI is essential for staging.

Tissue biopsy and pathology

To confirm the diagnosis, incisional biopsy is performed, and sufficient tissue is collected to differentiate from periodontal tissue. About 90% or more of gingival cancers are squamous cell carcinoma, and the degree of differentiation affects prognosis. Adenocarcinoma of minor salivary gland origin, malignant melanoma, and lymphoma are also included in the differential diagnosis. The pathology report should include depth of invasion, perineural invasion, lymphovascular invasion, resection margins, and bone invasion.

TNM staging (AJCC 8th edition)

T classification: T1 (≤2 cm, DOI ≤5 mm), T2 (>2–4 cm or DOI >5–10 mm), T3 (>4 cm or DOI >10 mm), T4a (invasion of cortical bone, maxillary sinus, or facial skin), T4b (invasion of the masticator space, pterygoid plates, skull base, or internal carotid artery). N classification is determined by size, number, laterality, and extranodal extension.


10. Treatment

For gingival cancer, surgery is the first-line standard treatment, and surgery is known to be more effective than radiation alone.

Surgery

When there is no bone invasion (T1-T2, cortical bone not invaded), marginal mandibulectomy is performed to preserve mandibular continuity. When there is medullary or segmental bone invasion, segmental mandibulectomy is performed, together with mandibular reconstruction using a fibula or iliac free bone flap. When DOI is 4 mm or more or the neck is clinically positive, ipsilateral selective neck dissection (level I-III) is performed. The goal is to secure a surgical resection margin of 5 mm or more, and positive margins are a strong risk factor for local recurrence.

Adjuvant radiation and chemoradiotherapy

In the presence of high-risk pathologic features (positive margins, perineural invasion, lymphovascular invasion, pN2 or higher, extracapsular extension), adjuvant radiotherapy using IMRT (60–66 Gy) or concurrent chemoradiotherapy (combined with cisplatin) is given. Because gingival cancer responds relatively poorly to radiotherapy alone, radiotherapy is used mainly as postoperative adjuvant treatment.

Recurrent/metastatic gingival cancer

Based on the KEYNOTE-048 results, pembrolizumab monotherapy (PD-L1 CPS≥1) or pembrolizumab combination therapy is used as first-line treatment. Based on CheckMate 141, nivolumab is used as second-line treatment after platinum failure. Cetuximab + EXTREME combination is also a first-line option.


11. Prognosis

Gingival cancer is a subtype of oral squamous cell carcinoma with a relatively poor prognosis, owing to diagnostic delay caused by its resemblance to periodontal inflammation and to early mandibular bone invasion.

Survival by stage

Survival indicatorsFigure
2-year overall survivalAbout 63.1%
5-year overall survival rateAbout 46.5%
10-year overall survivalAbout 28.1%
Early-stage (stage I–II) 5-year survivalAbout 65–75%
Advanced-stage (stage III–IV) 5-year survivalAbout 20–40%

Major prognostic factors

AJCC stage, presence of bone invasion, cervical lymph node metastasis (number, size, ENE), surgical margin status, histologic differentiation, and perineural invasion are independent prognostic factors. Diagnostic delay is the most important modifiable factor determining prognosis. Older age, male sex, and posterior mandibular location are associated with a poor prognosis.

Functional prognosis

The degree of recovery of masticatory, speech, and swallowing function after mandibular reconstruction varies with the reconstruction method and radiation field. After mandibular reconstruction with a fibula free flap, dental implants can be placed to help restore masticatory function.


12. Prevention

Primary prevention

Smoking cessation and moderation of alcohol intake are the most effective means of preventing gingival cancer. Use of chewing tobacco and betel nut should be stopped. Maintaining oral hygiene: minimize chronic periodontal inflammation through regular dental checkups, scaling, and oral cleanliness. Remove chronic mechanical irritation by correcting ill-fitting prostheses, retained roots, and sharp teeth.

Secondary prevention

Detection of precancerous lesions of the gingival mucosa at regular dental checkups (at least once a year) is key. A gum ulcer persisting for more than 2 weeks warrants a prompt visit to a medical facility. When precancerous lesions (leukoplakia, erythroplakia) are found, prompt biopsy and appropriate treatment (laser ablation, surgical excision) are required. Delayed wound healing after tooth extraction requires prompt biopsy to rule out malignancy.

Chemoprevention and other measures

Retinoid-based chemoprevention has been studied to a limited extent for the treatment of oral precancerous lesions. HPV vaccination is effective in preventing HPV-related oral cancer, but a direct effect on gingival cancer has not been established.


13. References

  1. Fu JH, Shin DM, Lin S, et al. Squamous cell carcinoma of the gingiva: A diagnostic enigma. Journal of Oral and Maxillofacial Pathology. 2015;19(3):400-406. DOI: 10.4103/0973-029X.174622

  2. Chi AC, Day TA, Neville BW. Oral mucosal lesions: A review for the practicing dentist. Journal of the American Dental Association. 2015;146(4):255-266. DOI: 10.1016/j.adaj.2015.01.011

  3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org

  4. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048). The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7

  5. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141). New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252

  6. Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.

  7. Zhang WB, Peng X. Which Clinicopathologic Factors Affect the Prognosis of Gingival Squamous Cell Carcinoma: A Population Analysis of 4,345 Cases. Journal of Oral and Maxillofacial Surgery. 2019;77(8):1674-1683. DOI: 10.1016/j.joms.2019.01.001

  8. Nomogram forecasting 3-, 5-, and 8-year overall survival and cancer-specific survival of gingival squamous cell carcinoma. Cancer Medicine. 2020;9(24):9315-9325. DOI: 10.1002/cam4.3543

  9. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834

  10. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. DOI: 10.3322/caac.21763